Lightnews — Scholar-powered news

As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity

Chris Burns @ampliaceo.bsky.social · 11d

New Data | Amplia’s ongoing ACCENT clinical trial in advanced pancreatic cancer has recorded an additional confirmed partial response and one unconfirmed partial response. Read the ASX release: bit.ly/3IQavFG
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma

Chris Burns @ampliaceo.bsky.social · 23d

As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity www.statnews.com/2025/09/25/m... via @statnews.com

As the U.S. dials back mRNA research, the U.K. is trying to seize an opportunity.

www.statnews.com

Chris Burns @ampliaceo.bsky.social · Sep 13

The diagnosis that saved me — and may have misled my mother to her death www.statnews.com/2025/09/10/m... via @statnews.com

The diagnosis that saved me — and may have misled my mother to her death

If I had not survived a rare misdiagnosis, would my mother have fought harder for her own treatment?

www.statnews.com

Reposted by Chris Burns

RSC Medicinal Chemistry @rscmedchem.rsc.org · Sep 1

🔓Read recent #OpenAccess work by Daohong Zhou, Guangrong Zheng & co on the potential of CRBN-recruiting Bcl-xL degraders as promising anticancer agents with improved efficacy and manageable platelet toxicity🔥

pubs.rsc.org/en/content/a...

📍 @ufresearch.bsky.social 🧪

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader

The conversion of conventional inhibitors of Bcl-xL, a key anti-apoptotic protein, to PROTAC degraders has shown significant promise, particularly in mitigating the on-target thrombocytopenia…

pubs.rsc.org

$72m boost for Australian medical research

Chris Burns @ampliaceo.bsky.social · Sep 1

$72m boost for Australian medical research www.innovationaus.com/72m-boost-fo...

More than $72 million in new medical research grants for projects ranging from chronic disease prevention and health equity to artificial intelligence in hospitals were announced by the federal govern...

Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients - Peter MacCallum Cancer Centre

Reposted by Chris Burns

WEHI (The Walter and Eliza Hall Institute of Medical Research) @wehi-research.bsky.social · Aug 31

Two WEHI-led projects tackling Parkinson’s and acute myeloid leukaemia have each received $3m in NHMRC funding over five years as newly announced Centres of Research Excellence.

🔗 Learn more and meet the project leads: www.wehi.edu.au/news/6m-boos...

Professor Grant Dewson (left) and Professor Andrew Wei (right)

1 3

Chris Burns @ampliaceo.bsky.social · Aug 31

Share www.petermac.org/about-us/new...

www.petermac.org

Chris Burns @ampliaceo.bsky.social · Aug 29

Amplia has announced opening of two Australian trial sites for the Company’s new pancreatic cancer trial investigating narmafotinib with FOLFIRINOX in metastatic pancreatic cancer patients.
Read the ASX release: bit.ly/ATX-Sites-Open

#pancreaticcancer #clinicaltrial #FOLFORINOX #FAK

ASX:ATX - AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL

Read and interact with this announcement: AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL on Amplia's investor hub

Let's not waste our multibillion-dollar biotech opportunity

Chris Burns @ampliaceo.bsky.social · Aug 19

Let’s not waste our multibillion-dollar biotech opportunity www.innovationaus.com/lets-not-was...

Australia’s life sciences industry is a quiet and unfortunately, regularly misunderstood achiever. With billions in annual revenues, the sector not only delivers world-class research, it also provides...

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors

Chris Burns @ampliaceo.bsky.social · Aug 7

Great to see this work, using Starpharma's drug, published.

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1...

PURPOSEThis early-phase study evaluated safety/tolerability, pharmacokinetics, and preliminary efficacy of dendrimer-nanoparticle delivery platform (DEP)-SN38, a polylysine-based nanoparticle conjugat...

ascopubs.org

Reposted by Chris Burns

Australian Academy of Science @science.org.au · Jul 11

Are you a top US-based scientist wanting to relocate to Australia? We are now calling for formal applications from both Australian and non-Australian citizens based in the US whose work is internationally recognised as exceptional.
📅 Applications close: Aug 29, 2025
🔗 science.org.au/gtap/?utm_so...

16 280 390

Chris Burns @ampliaceo.bsky.social · Aug 3

This is great news, though can't help to wonder where is BioCurate?
Monash’s $15m pre-seed fund backs first spinouts www.innovationaus.com/monashs-15m-...

Monash's $15m pre-seed fund backs first spinouts

Three Victorian HealthTech startups have secured pre-seed funding from Breakthrough Victoria and Monash University, marking the official launch of a new $15 million fund and the university’s new comme...

Qld super mandate directs $50m to local startups

Chris Burns @ampliaceo.bsky.social · Jul 30

Amplia has announced that it has received Australian ethics approval for the Ph2 trial of narmafotinib in combination with FOLFIRINOX in advanced pancreatic cancer.
Read the ASX release: bit.ly/ATX_AU_Ethics

$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics

Chris Burns @ampliaceo.bsky.social · Jul 29

Excellent news!!!
Qld super mandate directs $50m to local startups www.innovationaus.com/qld-super-ma...

A new $50 million investment mandate will see Queenslanders’ retirement savings channelled back into the state’s economy, with Brighter Super and Queensland Investment Corporation joining forces to ba...

Chris Burns @ampliaceo.bsky.social · Jul 11

Amplia Therapeutics has announced 17th confirmed partial response (PR) has been recorded in the Company’s ongoing ACCENT clinical trial in pancreatic cancer. Read the ASX release: bit.ly/ATX_17th_PR
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX

Amplia Therapeutics Limited

Reposted by Chris Burns

RSC Medicinal Chemistry @rscmedchem.rsc.org · Jun 19

This week's front cover features a Review by Taebo Sim and colleagues on the recent developments in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma, read it here👀

pubs.rsc.org/en/content/a...

📍Korea University and Yonsei University 🧪

RSC Medicinal Chemistry outside front cover for vol 16, issue 6.

1 1

Chris Burns @ampliaceo.bsky.social · Jun 19

#Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release tinyurl.com/33ez5srv

#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX

Read and interact with this announcement: Second Complete Response in ACCENT Pancreatic Cancer Trial on Amplia's investor hub

tinyurl.com

Registration | Twilight with PTX & ATX

Chris Burns @ampliaceo.bsky.social · Jun 16

I'll be speaking about narmafotinib and pipeline progress at #TwilightInvestorBriefing in Melbourne July 9th.

🔗 RSVP now: bit.ly/reg-twilight-ptx-atx

#ASX #biotech #oncology #pancreaticcancer

Date: Wed, 9 July 2025 Time: 4.15pm arrival for 4.30pm start Venue: Detail to be provided upon RSVP confirmation Inquiry: [email protected]

Amplia Therapeutics Limited

Chris Burns @ampliaceo.bsky.social · Jun 16

A patient from Amplia's ACCENT clinical trial in advanced pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the ASX release: bit.ly/ATX_pCR

$ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #ASX

Read and interact with this announcement: Pathological Complete Response in Pancreatic Cancer Trial on Amplia's investor hub

Dr Boreham's Crucible: This pancreatic cancer tackler has faith its 'good science will prevail' - Stockhead

Chris Burns @ampliaceo.bsky.social · May 27

Great to speak with Tim Boreham about Amplia Therapeutics' progress and plans. stockhead.com.au/health/dr-bo...

Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.

stockhead.com.au

Chris Burns @ampliaceo.bsky.social · May 16

New research shows combining FAK & MEK inhibitors is a promising strategy to tackle aggressive glioblastoma (GBM). This combination therapy significantly reduced tumor growth in models of disease
www.mdpi.com/1999-4923/17...
#glioblastoma #braintumor #targetedtherapy #FAK #MEK

@uoe-igc.bsky.social

www.mdpi.com

ASX:ATX - ACCENT Trial Achieves Superiority over Chemotherapy Alone

Chris Burns @ampliaceo.bsky.social · May 15

MILESTONE ACHIEVED | Amplia has announced 15 PRs in the ACCENT trial, demonstrating narmafotinib in combination with chemotherapy is superior to chemotherapy alone in advanced pancreatic cancer. Read the ASX release ampliatx.com/announcement...

#Amplia #pancreaticcancer #clinicaltrials #FAK

Read and interact with this announcement: ACCENT Trial Achieves Superiority over Chemotherapy Alone on Amplia's investor hub

ampliatx.com

Chris Burns @ampliaceo.bsky.social · May 12

Amplia Therapeutics has today announced the appointment of experienced oncologist and clinical trials specialist Dr Jason Lickliter MBBS, FRACP as Chief Medical Officer. Read the ASX Release: ampliatx.com/announcement...

#Amplia #pharma #clinicaltrials #cancer #oncology

Chris Burns @ampliaceo.bsky.social · May 11

Ed Husic: Ten years to build technology policy expertise www.innovationaus.com/ed-husic-ten...

Ed Husic: Ten years to build technology policy expertise

In his extraordinary interview on ABC TV’s Insiders program on Sunday, outgoing Industry and Science minister Ed Husic said he spent 10 years working and listening to understand the needs of the tech ...